Alternative and New Radiopharmaceutical Agents for Lung Cancer

Background: FDG PET/CT imaging has an established role in lung cancer (LC) management. Whilst it is a sensitive technique, FDG PET/CT has a limited specificity in the differentiation between LC and benign conditions and is not capable of defining LC heterogeneity since FDG uptake varies between histotypes. Objective: To get an overview of new radiopharmaceuticals for the study of cancer biology features beyond glucose metabolism in LC. Methods:...